Immunohistochemical expression of promyelocytic leukemia body in soft tissue sarcomasReportar como inadecuado

Immunohistochemical expression of promyelocytic leukemia body in soft tissue sarcomas - Descarga este documento en PDF. Documentación en PDF para descargar gratis. Disponible también para leer online.

Journal of Experimental and Clinical Cancer Research

, 27:73

First Online: 23 November 2008Received: 07 September 2008Accepted: 23 November 2008


BackgroundThe function of promyelocytic leukemia PML bodies is not well known but plays an important role in controlling cell proliferation, apoptosis and senescence. This study was undertaken to analyze the clinical significance of PML body expression in primary tumor samples from malignant fibrous histiocytoma MFH and liposarcoma patients.

MethodsWe studied MFH and liposarcoma samples from 55 patients for PML bodies. Fluorescent immunostaining of PML bodies was performed in the paraffin-embedded tumor sections.

ResultsPML body immunostaining was identified in 63.9% of MFH and 63.2% of liposarcoma samples. PML body expression rates of all sarcoma cells were 1.5 ± 1.8% range: 0–7.0 in MFH and 1.3 ± 1.4% 0–5.2 in liposarcoma samples. PML body expression p = 0.0053 and a high rate of PML body expression p = 0.0012 were significantly greater prognostic risk factors for death than the other clinical factors in MFH patients. All liposarcoma patients without expression of PML were disease free at the end of the study.

ConclusionOur study suggests that the presence of PML bodies may indicate a poor prognosis for MFH and liposarcoma patients.

Electronic supplementary materialThe online version of this article doi:10.1186-1756-9966-27-73 contains supplementary material, which is available to authorized users.

Download fulltext PDF

Autor: Toshihiro Matsuo - Takashi Sugita - Shoji Shimose - Tadahiko Kubo - Masataka Ishikawa - Yuji Yasunaga - Mitsuo Ochi


Documentos relacionados